U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose sharply during Wednesday's session after the company announced it intends to file a new drug application in January for AXS-12 after receiving feedback from the FDA. Additionally, the company announced the FDA granted Priority Review to AXS-05 for Alzheimer’s Agitation.Axsome Therapeutics shares surged 16.1% to $172.90 on Wednesday.Here are some other big stocks r ...

24/7 Wall St. Quick Read Nike CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that Apple’s Tim Cook bought $3 million worth of Nike stock. The U.S. FDA granted priority review of the Axsome’s marketing application seeking a label expansion for its depression therapy AXS-05 in Alzheimer’s disease agitation. Nvidia asked TSMC to help ramp up production of its H200 artificial intelligence chips. A recent study identified one single habit that doubled Americans’ retiremen ...

As Wednesday, December 31st, 2025, draws to a close, the U.S. stock market is wrapping up a remarkably strong year, despite a relatively subdued final trading session. Major indices opened with slight downward pressure today, reflecting a cautious mood as investors consolidate gains and look ahead to the new year. The S&P 500 (SPX), Nasdaq Composite (IXIC), and Dow Jones Industrial Average (DJIA) have all seen impressive annual growth, largely fueled by resilient corporate earnings and continued enthusiasm ...

美国制药商Vanda Pharmaceuticals(VNDA.US)大涨超26%，报8.9美元。消息面上，Vanda Pharmaceuticals 宣布，其用于预防运动诱发性呕吐的药物已获得美国食品药品监督管理局(FDA)批准，成为40多年来首 个获批的此类治疗药物。该公司预计将在未来几个月内推出这款名为Nereus的药物。(格隆汇) ...

Core Insights - Bayer has experienced a significant turnaround in 2025, with shares increasing by 121.6% over the past year, outperforming the industry gain of 19.2% and the S&P 500 Index [1][8]. Group 1: Performance and Market Position - Bayer's stock performance is attributed to new drug approvals, progress in its pipeline, improved Crop Science business performance, and positive updates on ongoing litigations [2]. - The company has outperformed the industry, sector, and S&P 500 Index, driven by FDA label expansions for drugs like Nubeqa and Kerendia, as well as approvals for Lynkuet and Hyrnuo [8]. - Nubeqa generated sales of €1.68 billion in the first nine months of 2025, compensating for the decline in Xarelto sales [9]. Group 2: Drug Approvals and Pipeline Progress - Bayer's pharmaceutical division is bolstered by new products such as Nubeqa and Kerendia, which have maintained strong momentum despite declining Xarelto sales [3]. - The FDA approved a label expansion for Kerendia, making it the only non-steroidal mineralocorticoid receptor antagonist approved in the U.S. for chronic kidney disease associated with type 2 diabetes and heart failure [4]. - Nubeqa received a label expansion for advanced prostate cancer, becoming the first FDA-approved androgen receptor inhibitor for hormone-sensitive prostate cancer [5][6]. - Bayer's pipeline includes promising candidates like gadoquatrane for MRI and asundexian for stroke prevention, with ongoing efforts to submit marketing authorization applications [13][14]. Group 3: Litigation and Financial Outlook - Bayer's stock received a boost from a favorable U.S. Supreme Court review signal regarding Roundup litigation, which has resulted in significant litigation costs [17][19]. - As of September 30, 2025, Bayer reserved $7.6 billion (€6.5 billion) for glyphosate litigation, with approximately 132,000 of nearly 197,000 claims resolved [19][20]. - From a valuation perspective, Bayer's shares trade at a price/earnings ratio of 7.59X forward earnings, below the industry average of 17X, indicating potential undervaluation [21]. - The Zacks Consensus Estimate for 2025 earnings per share has risen from $1.32 to $1.41, reflecting positive sentiment around the company's financial outlook [22].

Market Overview - U.S. stock markets are experiencing mixed premarket activity as 2025 comes to a close, following a three-day losing streak, despite significant annual gains driven by the AI and technology sectors [1][2] - Major U.S. market indexes are set to close 2025 with impressive annual gains: Nasdaq Composite is up approximately 21%, S&P 500 is up around 17%, and Dow Jones Industrial Average has climbed roughly 14% [5] Individual Stock Movements - Nike (NKE) shares rose 1.54% due to a significant stock purchase by CEO Elliott Hill [3] - Intel (INTC) gained 1.34% in premarket trading [3] - Autolus Therapeutics (AUTL) surged 5.35% after receiving a strategic upgrade from Needham & Co. [3] - Vanda Pharmaceuticals (VNDA) experienced a significant jump of 18.7% following FDA approval for its drug [3] - DigitalBridge Group (DBRG) shares surged 9.6% on news of acquisition by SoftBank Group Corp. valued at approximately $4 billion [13] - Ultragenyx Pharmaceutical (RARE) shares plunged 42.3% after disappointing Phase 3 trial results [13] - Tesla (TSLA) forecasted a decrease in fourth-quarter sales, expecting to sell 1.64 million vehicles in 2025 [13] Technology Sector Highlights - Nvidia (NVDA) remains a dominant player in AI, with ByteDance planning to increase spending on Nvidia's AI chips to ¥100 billion ($14 billion) in 2026 [13] - Meta Platforms (META) acquired AI startup Manus for over $2 billion [13] - Caterpillar (CAT) saw stock surges attributed to sales of generators related to AI infrastructure [13] Economic Data and Federal Reserve Insights - Initial Jobless Claims reported at 199,000, below the expected 220,000, indicating a slowing but stable labor market [7] - The Federal Reserve's recent meeting minutes revealed a divided debate on interest rate cuts, with expectations for further reductions in 2026 [6]

12月29日，又一药企复合磷酸氢钾注射液（膳维喜）获国家药监局批准上市，作为磷酸补充剂用于临床。这款年销超4亿元、同比增长27.3%的临床"硬通 货"，在持续增长的市场中迎来了又一位竞争者。 在这次获批前，国内已有24家药企拥有该品种的生产批文，其中19家已通过一致性评价，市场竞争格局已相当稳定。然而，申报热情不减。目前仍有15家药 企提交了3类仿制药上市申请，正处于审评审批的阶段。这反映出企业对该品种市场价值的持续看好。 截图来源：全终端医院销售数据库 截图来源：企业公告 复合磷酸氢钾注射液是临床纠正成人及儿童低磷血症的关键药物，尤其在患者无法经口补充时，是维持生命体征稳定的静脉磷钾"精准补给方案"。与常规营 养制剂不同，其定位于满足特定临床场景下的电解质精准补充，属于治疗性刚需。该品种被纳入国家医保乙类目录多年，临床认知与使用已高度成熟。 市场数据印证了其价值。据摩熵医药数据库显示，该品种近三年在全终端医院市场保持稳定增长，2024年销售额突破4亿元，同比增长27.3%，在血液代用 品与灌注液品类中稳居市场前列。此次获批，正值该市场处于明确的扩容时期。 | 按受理号浏览(13) | 按品种浏览(1) | ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets delivered solid results in the third quarter, driven by the resolution of significant trade conflicts and a shift in U.S. monetary policy toward a more dovish stance. Baird Chautauqua International Growth Fund underperformed the ...

新华财经北京12月31日电（胡晨曦） 在BD（商务拓展）出海大单持续超预期等催化下，创新药板块 2025年表现亮眼。尽管近期连续调整，但港股创新药指数（931787.CSI）等创新药代表性指数年内涨幅 仍近70%。个股方面，截至A股12月31日收盘，舒泰神、三生国健、荣昌生物、昭衍新药等个股股价年 内实现翻倍。 展望2026年，业内人士普遍看好在产业政策对真创新、高水平创新的支持下，大量创新药BD将密集落 地。商保实施与集采优化双轮推动下，创新药产业链高景气度有望延续，高价值创新药有望迎来第二增 长曲线。 个股表现抢眼医药企业蜂拥港股 今年以来，二级市场上创新药板块表现十分亮眼。 其中，A股方面，截至12月31日收盘，舒泰神、三生国健、荣昌生物、昭衍新药等个股股价实现翻倍， 其中舒泰神年内股价曾一度暴涨近7倍。港股方面，年初至今，荣昌生物、三生制药涨超300%，信达生 物、翰森制药、诺诚健华、药明合联等多股涨超100%。此外，2025年初至今，港股创新药指数 （931787.CSI）涨约72.5%，其间一度飙升逾100%。A股创新药板块同样大涨，1月10日至9月8日，中证 创新药（931152.CSI）指数累 ...

Key Takeaways VNDA won FDA approval for tradipitant, branded Nereus, to prevent vomiting caused by motion sickness.Vanda Pharmaceuticals said Nereus is the first new motion sickness drug in more than 40 years.VNDA shares surged 18% after hours following the approval, extending gains into pre-market trading.Vanda Pharmaceuticals, Inc. (VNDA) announced that the FDA has approved its candidate tradipitant for the prevention of vomiting induced by motion.The drug has been approved under the brand name Nereus.Tra ...